AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12692051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily (n=259)
Number of subjects: 520
Study 12692051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=261)
Number of subjects: 520
Study 11083356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (1.06-microm continuous wave laser emitting 204 mW/cm2 for 60 seconds at 7 points along the symptomatic forearm, 3 times weekly for 4 weeks)
Number of subjects: 52
Study 11083356 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive laser treatment)
Number of subjects: 52
Study 11083356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy
Number of subjects: 52
Study 11083356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 8810592 — intervention group
Group type: COMPARATOR
Intervention: Whole-blood PMN and alveolar PMN obtained by bronchoalveolar lavage (BAL) in ARDS patients
Number of subjects: 29
Study 8810592 — intervention group
Group type: COMPARATOR
Intervention: Ex vivo stimulation of alveolar PMN by a bacterial peptide
Number of subjects: 29
Study 8810592 — intervention group
Group type: COMPARATOR
Intervention: Degree of PMN activation
Number of subjects: 29
Study 7930301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (10 mg)
Number of subjects: 17
Study 7930301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 17
Study 7930301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two puffs)
Number of subjects: 17
Study 3687822 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (15-20% energy from fat)
Number of subjects: 24
Study 3687822 — intervention group
Group type: COMPARATOR
Intervention: Medium-fat diet (30-35% energy from fat)
Number of subjects: 24
Study 3687822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (45-50% energy from fat)
Number of subjects: 24
Study 3687822 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 24
Study 30013701 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated position
Number of subjects: 42
Study 30013701 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 42
Study 28915904 — intervention group
Group type: EXPERIMENTAL
Intervention: manualised Psychoanalytic Child Psychotherapy (mPCP)
Number of subjects: 60
Study 28915904 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 60
Study 24447183 — intervention group
Group type: EXPERIMENTAL
Intervention: HTNV DNA vaccine (2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Number of subjects: 27
Study 24447183 — intervention group
Group type: EXPERIMENTAL
Intervention: PUUV DNA vaccine (2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Number of subjects: 27
Study 24447183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HTNV and PUUV DNA vaccines (1.0 mg each, 2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Number of subjects: 27
Study 23169276 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advocate nurse-led intervention (usual and customary plus additional services from Cigna)
Number of subjects: 0
Study 23169276 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary services (control group)
Number of subjects: 0
Study 23169276 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advocate nurse-led intervention
Number of subjects: 0
Study 19762206 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program (SEP)
Number of subjects: 178
Study 19762206 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 178
Study 19762206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy (PTA + SEP)
Number of subjects: 178
Study 19762206 — intervention group
Group type: COMPARATOR
Intervention: PTA + SEP
Number of subjects: 178
Study 17693146 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial temporal artery (STA) and facial artery (FA) pedicle technique
Number of subjects: 6
Study 17693146 — intervention group
Group type: COMPARATOR
Intervention: External carotid artery (ECA) pedicle technique
Number of subjects: 6
Study 15765240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypergravity with ergometric exercise (30 min at +1.2 Gz acceleration, 60 W for 4 subjects, 40 W for 2 subjects)
Number of subjects: 12
Study 15765240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypergravity exercise)
Number of subjects: 12
Study 12144577 — intervention group
Group type: EXPERIMENTAL
Intervention: BTF (Bismuth, Tetracycline, Furazolidone)
Number of subjects: 70
Study 12144577 — intervention group
Group type: COMPARATOR
Intervention: OBTM (Omeprazole, Bismuth, Tetracycline, Metronidazole)
Number of subjects: 70
Study 12144577 — intervention group
Group type: EXPERIMENTAL
Intervention: BTF
Number of subjects: 70
Study 12144577 — intervention group
Group type: COMPARATOR
Intervention: OBTM
Number of subjects: 70
Study 9850002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt tympanostomy tube placement
Number of subjects: 0
Study 9850002 — intervention group
Group type: COMPARATOR
Intervention: Delayed tympanostomy tube placement
Number of subjects: 0
Study 7755003 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-effects regression model for analysis of clustered data
Number of subjects: 0
Study 7755003 — intervention group
Group type: COMPARATOR
Intervention: Ordinary regression analysis of clustered data
Number of subjects: 0
Study 7755003 — intervention group
Group type: COMPARATOR
Intervention: Cluster-level analysis
Number of subjects: 0
Study 3133327 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and adjuvant estrogen (diethylstilbestrol)
Number of subjects: 78
Study 3133327 — intervention group
Group type: COMPARATOR
Intervention: Radiation only
Number of subjects: 78
Study 31583533 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin + Lactulose
Number of subjects: 87
Study 31583533 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 87
Study 29332240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal closed-system suction drainage
Number of subjects: 90
Study 29332240 — intervention group
Group type: COMPARATOR
Intervention: No-drain
Number of subjects: 90
Study 25536639 — intervention group
Group type: EXPERIMENTAL
Intervention: TVR-standard group (2,250 mg TVR for 12 weeks plus reduced ribavirin dose)
Number of subjects: 62
Study 25536639 — intervention group
Group type: EXPERIMENTAL
Intervention: TVR-reduced group (1,500 mg TVR plus standard ribavirin dose)
Number of subjects: 62
Study 25536639 — intervention group
Group type: COMPARATOR
Intervention: TVR-standard group
Number of subjects: 62
Study 25536639 — intervention group
Group type: COMPARATOR
Intervention: TVR-reduced group
Number of subjects: 62
Study 25536639 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 62
Study 23190874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 29
Study 23190874 — intervention group
Group type: COMPARATOR
Intervention: Fish oil supplements
Number of subjects: 29
Study 21481003 — intervention group
Group type: EXPERIMENTAL
Intervention: New gustatory stimulant of salivary secretion (GSSS) containing weaker malic acid, fluoride, and xylitol
Number of subjects: 80
Study 21481003 — intervention group
Group type: COMPARATOR
Intervention: Traditional citric acid-based gustatory stimulant of salivary secretion (GSSS)
Number of subjects: 80
Study 18421507 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop orders for indwelling urinary catheters
Number of subjects: 692
Study 18421507 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 692
Study 16931252 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired opposite clear corneal incisions (OCCIs)
Number of subjects: 40
Study 16931252 — intervention group
Group type: COMPARATOR
Intervention: Single clear corneal incisions (CCIs)
Number of subjects: 40
Study 12673261 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue LED phototherapy
Number of subjects: 114
Study 12673261 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green LED phototherapy
Number of subjects: 114
Study 12673261 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 114
Study 10714690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cyclopentolate 0.2% and phenylephrine 1% eyedrops
Number of subjects: 28
Study 10714690 — intervention group
Group type: COMPARATOR
Intervention: Triple instillation of tropicamide 0.5% and phenylephrine 2.5%
Number of subjects: 28
Study 9424323 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAF/MCP1 concentrations in BALF from patients with chronic bronchitis
Number of subjects: 32
Study 9424323 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients aged 30.5 +/- 3.4 years)
Number of subjects: 32
Study 1576488 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of salmon calcitonin and 500 mg of elemental calcium for 10 consecutive days each month
Number of subjects: 32
Study 1576488 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of elemental calcium only for 10 consecutive days each month
Number of subjects: 32
Study 3907580 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 3907580 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 30982716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication (paracetamol, opioids, or both)
Number of subjects: 407
Study 30982716 — intervention group
Group type: COMPARATOR
Intervention: No pain medication
Number of subjects: 407
Study 30982716 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 407
Study 30202939 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief manualised group intervention on the interrelation of AUD and MD or PTSD
Number of subjects: 171
Study 30202939 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training session (control group)
Number of subjects: 171
Study 27041272 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon block with mixture of 4 mL of 2% lidocaine and 0.5% bupivacaine (50:50)
Number of subjects: 80
Study 27041272 — intervention group
Group type: COMPARATOR
Intervention: Subtenon injection of saline
Number of subjects: 80
Study 23996878 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intensity‐modulated radiation therapy (IMRT)
Number of subjects: 88
Study 23996878 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT)
Number of subjects: 88
Study 22499521 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide intramuscular injection after swallowing the capsule
Number of subjects: 116
Study 22499521 — intervention group
Group type: COMPARATOR
Intervention: No metoclopramide administered (Control)
Number of subjects: 116
Study 22499521 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide intramuscular injection
Number of subjects: 116
Study 20727717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community care
Number of subjects: 337
Study 20727717 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (Omega-3 PUFAs) supplementation
Number of subjects: 337
Study 20727717 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused treatment groups (various interventions)
Number of subjects: 337
Study 20727717 — intervention group
Group type: COMPARATOR
Intervention: Control UHR groups (no treatment or treatment as usual)
Number of subjects: 337
Study 20727717 — intervention group
Group type: EXPERIMENTAL
Intervention: Any focused treatment
Number of subjects: 337
Study 19227196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff compression (250 mmHg) for 10 min
Number of subjects: 10
Study 19227196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff compression (250 mmHg) for 26 min
Number of subjects: 10
Study 19227196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff compression (250 mmHg) for both 10 min and 26 min
Number of subjects: 10
Study 16199148 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg bid plus terbutaline 0.5 mg as needed (FORM bid)
Number of subjects: 657
Study 16199148 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg bid plus formoterol 4.5 microg as needed (FORM bid+prn)
Number of subjects: 657
Study 16199148 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid plus terbutaline 0.5 mg as needed (placebo)
Number of subjects: 657
Study 11898986 — intervention group
Group type: EXPERIMENTAL
Intervention: Free riding with justification (justified by low ability)
Number of subjects: 97
Study 11898986 — intervention group
Group type: EXPERIMENTAL
Intervention: Free riding
Number of subjects: 97
Study 11898986 — intervention group
Group type: EXPERIMENTAL
Intervention: No free riding
Number of subjects: 97
Study 10626340 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment + complex of amino acids (100 mg 3 times a day sublingually)
Number of subjects: 60
Study 10626340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant preductal (20 mg 3 times a day per os for 20 days)
Number of subjects: 60
Study 10626340 — intervention group
Group type: COMPARATOR
Intervention: Conventional antianginal therapy (nitrates, beta-adrenoblockers, calcium antagonists, diuretics, ACI inhibitors, cardiac glycosides, and aspirin)
Number of subjects: 60
Study 8520738 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPSS) at 1 gm intravenously 5 min before CPB (Group S)
Number of subjects: 20
Study 8520738 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group N)
Number of subjects: 20
Study 8520738 — intervention group
Group type: COMPARATOR
Intervention: Control group of 10 patients undergoing repair of infrarenal aortic aneurysms
Number of subjects: 20
Study 1836810 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting GnRH-a (Decapeptyl) and hMG
Number of subjects: 175
Study 1836810 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting GnRH-a (Buserelin) and hMG
Number of subjects: 175
Study 1836810 — intervention group
Group type: COMPARATOR
Intervention: hMG only
Number of subjects: 175
Study 7020141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin intravenously, 1 gm 2 hours prior to surgery, at induction of anesthesia, and then 0.5 gm every 6 hours for 48 hours
Number of subjects: 53
Study 7020141 — intervention group
Group type: COMPARATOR
Intervention: Placebo of 5% dextrose at identical intervals
Number of subjects: 53
Study 30160635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 82
Study 30160635 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 82
Study 30160635 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 82
Study 28935269 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3 supplementation (962mg/d for children and 1155mg/d for adolescents)
Number of subjects: 68
Study 28935269 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3 supplementation
Number of subjects: 68
Study 26292674 — intervention group
Group type: EXPERIMENTAL
Intervention: HypoAware intervention (three group sessions and two online modules)
Number of subjects: 154
Study 26292674 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 154
Study 26292674 — intervention group
Group type: EXPERIMENTAL
Intervention: HypoAware intervention
Number of subjects: 154
Study 23383726 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling intervention (problem-solving therapy approach)
Number of subjects: 100
Study 23383726 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 100
Study 21062674 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 107
Study 21062674 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections of insulin (MDI)
Number of subjects: 107
Study 21062674 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring systems (CGMS)
Number of subjects: 107
Study 21062674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CSII and MDI
Number of subjects: 107
Study 19167731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (60 to 64 Gy)
Number of subjects: 431
Study 19167731 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 431
Study 17087947 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib
Number of subjects: 2587
Study 17087947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2587
Study 15598478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination latanoprost 0.005% + timolol maleate 0.5% QD
Number of subjects: 350
Study 15598478 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% QD
Number of subjects: 350
Study 11511562 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 1.25 mg
Number of subjects: 270
Study 11511562 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 2.5 mg
Number of subjects: 270
Study 11511562 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 5 mg
Number of subjects: 270
Study 11511562 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 10 mg
Number of subjects: 270
Study 11511562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 9250116 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg/d)
Number of subjects: 491
Study 8173702 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180-360 mg daily)
Number of subjects: 12000
Study 8173702 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (diuretics or beta-adrenergic blockers)
Number of subjects: 12000
Study 3507006 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef extended with soy isolate, soy concentrate, or soy flour (20% reconstituted soy product, 80% beef)
Number of subjects: 52
Study 3507006 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef extended with soy products fortified with 60 mg Fe and 25 mg Zn/100 g protein
Number of subjects: 52
Study 3507006 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming their usual self-selected diet
Number of subjects: 52
Study 31830761 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight mothers
Number of subjects: 935
Study 31830761 — intervention group
Group type: COMPARATOR
Intervention: R-BMI mothers
Number of subjects: 935
Study 29534403 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dosage of fasudil (30 mg)
Number of subjects: 60
Study 29534403 — intervention group
Group type: EXPERIMENTAL
Intervention: Large dosage of fasudil (60 mg)
Number of subjects: 60
Study 29534403 — intervention group
Group type: COMPARATOR
Intervention: Comparison between large dosage and regular dosage groups
Number of subjects: 60
Study 26603174 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine)
Number of subjects: 252
Study 26603174 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (target dose 25 mg/kg)
Number of subjects: 252
Study 26603174 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 252
Study 26603174 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 252
Study 24684390 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine
Number of subjects: 22
Study 24684390 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 22594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon oil and pogostemon oil complex
Number of subjects: 60
Study 22594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon oil
Number of subjects: 60
Study 22594097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pogostemon oil
Number of subjects: 60
Study 21199118 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-handled Macintosh laryngoscope
Number of subjects: 40
Study 21199118 — intervention group
Group type: COMPARATOR
Intervention: Pediatric Bullard laryngoscope
Number of subjects: 40
Study 16962170 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin users
Number of subjects: 600
Study 16962170 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular acetaminophen users
Number of subjects: 600
Study 16962170 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater frequency of acetaminophen use (>7 tablets weekly)
Number of subjects: 600
Study 16962170 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater duration of acetaminophen use (>10 years)
Number of subjects: 600
Study 16260979 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte solution (CHO)
Number of subjects: 9
Study 16260979 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (PLA)
Number of subjects: 9
Study 12079632 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) at 1000 units (conversion of 50 units of BTX‐B to 1 unit of BTX‐A)
Number of subjects: 0
Study 12079632 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) at 2000 units (conversion of 100 units of BTX‐B to 1 unit of BTX‐A)
Number of subjects: 0
Study 12079632 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A (BTX‐A) at 20 units
Number of subjects: 0
Study 10467790 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated 2-rod Norplant implant
Number of subjects: 11
Study 7604806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin at 20 mg twice daily
Number of subjects: 17
Study 7604806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil at 600 mg twice daily
Number of subjects: 17
Study 7604806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin and gemfibrozil
Number of subjects: 17
Study 2123072 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) administered within 4 hours from symptom onset (group A)
Number of subjects: 60
Study 2123072 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) administered between 4 and 8 hours from symptom onset (group B)
Number of subjects: 60
Study 2123072 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (group C)
Number of subjects: 60